Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.

"Treatable traits" have been proposed as a new paradigm for the management of airway diseases, particularly complex disease, which aims to apply personalised medicine to each individual to improve outcomes. Moving new treatment approaches from concepts to practice is challenging, but necessary. In an effort to accelerate progress in research and practice relating to the treatable traits approach, the Treatable Traits Down Under International Workshop was convened in Melbourne, Australia in May 2018. Here, we report the key concepts and research questions that emerged in discussions during the meeting. We propose a programme of research that involves gaining international consensus on candidate traits, recognising the prevalence of traits, and identifying a potential hierarchy of traits based on their clinical impact and responsiveness to treatment. We also reflect on research methods and designs that can generate new knowledge related to efficacy of the treatable traits approach and consider multidisciplinary models of care that may aid its implementation into practice.

Informations de copyright

Copyright ©ERS 2019.

Déclaration de conflit d'intérêts

Conflict of interest: V.M. McDonald reports grants from GlaxoSmithKline during the conduct of the meeting; and grants and speaker fees from GlaxoSmithKline and AstraZeneca, personal fees for meeting organisation from Menarini, and grants from Cyclopharm Ltd, outside the submitted work. Conflict of interest: J. Fingleton reports travel to the educational event “Treatable Traits Down Under”, at which the ideas contained within this paper were developed, from GlaxoSmithKline; speaker fees for educational events and support to attend educational events from AstraZeneca Ltd and Boehringer Ingelheim, and grants from GlaxoSmithKline and Fisher & Paykel Ltd, New Zealand, outside the submitted work. Conflict of interest: A. Agusti reports grants and personal fees from AstraZeneca and Menarini, and personal fees from Chiesi, GlaxoSmithKline, Nuvaira and Boehringer Ingelheim, outside the submitted work. Conflict of interest: S.A. Hiles’ salary was supported by a grant from GlaxoSmithKline, paid to her institution (University of Newcastle), during the conduct of the meeting. S.A. Hiles also reports salary from a grant from AstraZeneca, paid to her institution, outside the submitted work. Conflict of interest: V.L. Clark receives a fellowship from the National Health and Medical Research Council Centre of Research Excellence in Severe Asthma. Conflict of interest: A.E. Holland has nothing to disclose. Conflict of interest: G.B. Marks reports grants from GlaxoSmithKline (Australia) and from AstraZeneca (Australia), outside the submitted work. Conflict of interest: P.P. Bardin reports personal fees from GlaxoSmithKline, Boehringer Ingelheim and AstraZeneca, during the conduct of the study. Conflict of interest: R. Beasley reports grants from the Health Research Council of New Zealand, grants and personal fees from AstraZeneca and GlaxoSmithKline, and grants from Genentech, outside the submitted work. Conflict of interest: I.D. Pavord reports personal fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Sanofi/Regeneron, Circassia, Merck, Novartis, Mundipharma, Teva, Knopp and Roche/Genentech, and grants and personal fees from Afferent and Chiesi, outside the submitted work. Conflict of interest: P.A.B. Wark receives grants from The University of Newcastle, John Hunter Hospital Charitable Trust, grants from Hunter Medical Research Institute, grants from National Health and Medical Research Council, during the conduct of the study; he has taken part in advisory boards for AstraZeneca, Boehringer Ingelheim, Novartis and Vertex, and has received personal fees from AstraZeneca, GlaxoSmithKline and Vertex, outside the submitted work. Conflict of interest: P.G. Gibson reports grants and personal fees from AstraZeneca, GlaxoSmithKline and Novartis, and grants from NHMRC (Australian Government), outside the submitted work.